L-DOPA remains the most effective therapy in the management of the motor symptoms of Parkinson's disease (PD). However, chronic treatment with levodopa is associated with the risk of development of motor fluctuations such as choreic and dystonic abnormal and involuntary movements affecting mainly the upper...
As you know Syncrosome is a preclinical CRO managing efficacy in vivo/ in vitro studies with more than 15 disease models validated in house and reproducible. Syncrosome is involved in Central Nervous System activities for 16 years with a specific department dedicated to several CNS disease...
Syncrosome is just launching its new website. This is the result of the collaboration between Syncrosome’s internal team, consultants and customers: www.syncrosome.com. Thank you for your collaboration, and we hope you will find all information you are looking for! Please do not hesitate to visit it and...
Syncrosome, a Preclinical CRO specialized in in vivo efficacy experiments, is pleased to welcome our new colleague, Caroline Babuleaud-Casano as our new Technical Manager. Caroline hold 2 MSc., 1 in Neurosciences and 1 in Neuro-pharmacology. During her 10 years professional experience, she has been working on various...
Vaccination is increasingly being investigated as a potential treatment for synucleinopathies, a group of neurodegenerative diseases including Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies associated with α-synuclein pathology. All lack a causal therapy. Development of novel, disease-altering treatment strategies is urgently needed....
Parkinson’s disease, multiple system atrophy and dementia with Lewy bodies, have all something in common. They all belong to a group of neurodegenerative diseases called synucleinopathies, including preclinical Parkinson, characterized by the abnormal accumulation of aggregates of α-synuclein protein in neurons, nerve fibres or glial...
Researchers from the CHU Research centre in Quebec have shown that diet can play a neuroprotective role in a preclinical Parkinson mouse model. They investigated the effects of a omega-3 polyunsaturated fatty acids-enriched diet, in the form of docosahexaenoic acid (DHA), on damaged neurons. C57BL/6...
Syncrosome, a Preclinical CRO specialized in in vivo efficacy experiments, is pleased to welcome Dr Viviana Delgado Betancourt as our new Cardiovascular Study Director. Viviana brings to the table several years of experience acquired over the courseof her thesis/PhD that focused on cardioprotection against Ischemia-Reperfusion injury...
Below a poster presented by Syncrosome during the last European Respiratory Society meeting showing interesting result concerning Pulmonary Arterial Hypertension induced on rats with Sugen with remodeling in small pulmonary arteries (PAH sugen). Results are reproducible and shows a vascular remodeling, increased Right Ventricular Systolic Pressure...
This poster has been presented at the last 2015 World Parkinson Congress in France, and shows interesting results concerning an antidyskinetic compound in a rat 6 OHDA Parkinson model. Dyskinesias are induced by LDopa, and various parameters are assessed, biochemical and symptomatic. Microdialysis is used to evaluate...